-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $617

Benzinga·08/05/2026 13:30:55
语音播报
Barclays analyst Eliana Merle maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $615 to $617.